Business Context and Reporting Period
Company: SIGA Technologies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2007
Business Overview: SIGA is a bio-defense company focused on the discovery, development, and commercialization of products to defend against biological warfare agents (e.g., smallpox, Arenaviruses) and novel anti-infectives. The company has no commercial products and relies on government contracts, grants, and strategic alliances for funding.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2007 |
Nine Months Ended Sep 30, 2007 |
Nine Months Ended Sep 30, 2006 |
|---|---|---|---|
| Revenues | $1,609,123 | $4,936,258 | $4,888,987 |
| Net Loss | $(2,493,296) | $(5,108,225) | $(5,647,409) |
| Net Loss Per Share (Basic/Diluted) | $(0.07) | $(0.15) | $(0.21) |
| Cash and Cash Equivalents | $8,065,733 | $8,065,733 (End of Period) | $2,649,684 (End of Period) |
| Working Capital | $7,526,200 | $7,526,200 | $9,347,664 |
| Notes Payable | $0 | $0 | $130,329 (Repayment) |
Liquidity: As of September 30, 2007, the company held $8.1 million in cash and cash equivalents. Management believes existing cash balances combined with anticipated cash flows from government contracts and grants will support operations beyond the next twelve months.
Material Changes vs. Prior Period
- Revenue: For the nine months ended September 30, 2007, revenue remained relatively flat at approximately $4.9 million compared to $4.9 million in the prior year. However, the mix shifted: NIH contracts and grants accounted for 65% of revenue in 2007 (up from 51% in 2006), while U.S. Army and Air Force contracts decreased to 35% (down from 49%).
- Operating Expenses: Total operating expenses increased to $10.3 million for the nine months ended September 30, 2007, from $9.7 million in the prior year.
- R&D Expenses: Increased by 15.2% ($7.2 million vs. $6.2 million) due to higher payroll expenses ($480,000 increase) and increased clinical/pre-clinical testing costs ($820,000 increase).
- SG&A Expenses: Decreased to $2.8 million from $3.2 million, primarily due to the absence of significant professional fees and non-cash consulting charges related to a potential business transaction that occurred in 2006.
- Non-Operating Items: The company recorded a loss of $32,000 for the nine months ended September 30, 2007, related to the increase in fair market value of common stock warrants. This compares to a loss of $721,000 in the same period in 2006.
- Cash Flow: Net cash used in operating activities increased to $4.4 million in 2007 from $2.9 million in 2006, driven by increased R&D spending and a $400,000 increase in accounts receivable.
Guidance, Outlook, and Risks
- Outlook: SIGA does not expect to have commercial products for one to three years, if at all. The company anticipates incurring operating losses for the foreseeable future. Management estimates the cost to complete the lead program (ST-246) will be approximately $15 million to $20 million over 24 to 36 months.
- Development Progress:
- ST-246 (Smallpox): Received FDA Fast-Track status (Dec 2005) and Orphan Drug designation (Dec 2006). 21-day dose-escalating studies began in 2007.
- Hemorrhagic Fevers: Supported by NIH SBIR grants totaling $6.3 million previously, plus a new $6.0 million grant received in September 2006.
- Risks and Contingencies:
- Litigation: PharmAthene, Inc. filed a lawsuit in December 2006 seeking a license agreement for SIGA-246 and damages. SIGA filed a motion to dismiss, which is pending a court decision. SIGA believes the claims are without merit.
- Financing: There is no assurance the company will obtain sufficient future financing on commercially reasonable terms or secure anticipated government contracts.
- Going Concern: While management believes cash is sufficient for the next 12 months, the company has incurred cumulative net losses and has limited capital resources.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $8.1 million cash balance against projected R&D burn rates and the timeline for ST-246 clinical trials.
- Litigation Status: Monitor the outcome of the PharmAthene, Inc. v. SIGA Technologies, Inc. lawsuit, as a loss could result in significant damages or forced licensing of the lead asset.
- Government Funding Dependency: Assess the risk associated with 65% of revenue coming from NIH contracts and grants; verify the status of upcoming grant renewals.
- Warrant Liability: Review the fair value adjustments of outstanding warrants (classified as liabilities), which caused a $32,000 loss in the period and could impact future earnings volatility.
- Accounts Receivable: Investigate the $400,000 increase in accounts receivable to ensure collectibility, particularly given the reliance on government payors.